Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
LGVN
LGVN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LGVN News
Longeveron Advances FDA Discussions on ELPIS II Trial
6h ago
NASDAQ.COM
Longeveron Advances Phase 2b Trial for HLHS
1h ago
Newsfilter
FDA Raises Concerns Over Longeveron's Cell Therapy Trial Design
2d ago
stocktwits
Longeveron Discusses ELPIS II with FDA
2d ago
Newsfilter
Avaí Bio Advances Anti-Aging Therapeutics Development
Apr 23 2026
Globenewswire
Avaí Bio Advances Longevity Therapeutics Development
Apr 23 2026
Newsfilter
Avaí Bio Advances Cell Therapy for Aging
Apr 10 2026
PRnewswire
Avaí Bio and Austrianova Advance Anti-Aging Therapy Collaboration
Apr 10 2026
Newsfilter
Longeveron Secures Patent for Potency Assay Methods in China
Apr 08 2026
Newsfilter
LONGEVERON RECEIVES CHINESE PATENT FOR METHODS TO ASSESS POTENCY OF HUMAN MESENCHYMAL STEM CELLS (MSCS)
Apr 08 2026
moomoo
Avaí Bio Initiates Production of α-Klotho Cell Bank
Mar 18 2026
Globenewswire
Avaí Bio Initiates Production of α-Klotho Cells
Mar 18 2026
PRnewswire
Avaí Bio Initiates α-Klotho Cell Production
Mar 18 2026
Newsfilter
Longeveron (LGVN) Q4 2025 Earnings Call Transcript
Mar 18 2026
NASDAQ.COM
Longeveron Reports FY EPS Beat but Increased Losses
Mar 17 2026
seekingalpha
Longeveron Raises $15M to Advance Laromestrocel Therapy
Mar 10 2026
Benzinga
Show More News
